Some measures of success continued to improve in men with type 2 diabetes on testosterone replacement therapy. Others reverted to the norm of the placebo group. The abstract says:
"Improvement in HbA1c and weight at the end of the RCT [randomized clinical trial] and open-label phase in men on TRT [testosterone replacement therapy] was not maintained long-term. The convergence in HbA1c could have been due to incentivised care with HbA1c targets. Interestingly those on TRT at final assessment required fewer anti-diabetic agents. The weight increase in routine care may have been due to changes in diabetes medication or an increase in lean muscle mass. WC [waist circumference] continued to decrease in men on TRT indicating possible reduction in visceral fat. Improvement in EF [erectile function] scores continued with long-term TRT, this was abolished when TRT was discontinued."
"Improvement in HbA1c and weight at the end of the RCT [randomized clinical trial] and open-label phase in men on TRT [testosterone replacement therapy] was not maintained long-term. The convergence in HbA1c could have been due to incentivised care with HbA1c targets. Interestingly those on TRT at final assessment required fewer anti-diabetic agents. The weight increase in routine care may have been due to changes in diabetes medication or an increase in lean muscle mass. WC [waist circumference] continued to decrease in men on TRT indicating possible reduction in visceral fat. Improvement in EF [erectile function] scores continued with long-term TRT, this was abolished when TRT was discontinued."
